Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
Defence Therapeutics (DTCFF) Stock Price & Analysis
9 Followers
DTCFF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $2.74
Previous Close$0.6
Volume500.00
Average Volume (3M)1.14K
Market Cap
$26.38M
Enterprise Value$27.22M
Total Cash (Recent Filing)C$351.00K
Total Debt (Recent Filing)C$1.51M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Nov 22, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding45,536,673
10 Day Avg. Volume300
30 Day Avg. Volume1,140
Standard Deviation0.46
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-16.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Defence Therapeutics News
PremiumCompany Announcements
Defence Therapeutics’ AccuTOX Enhances Cancer Treatment
PremiumCompany Announcements
Defence Therapeutics’ Vaccine Shows Promising Results
PremiumCompany Announcements
Defence Therapeutics Showcases Cancer Tech Breakthroughs
PremiumCompany Announcements
Defence Therapeutics to Showcase Cancer AdvancesPremiumCompany Announcements
Defence Therapeutics’ AccuTOX Shows Cancer-Fighting PromisePremiumCompany Announcements
Defence Therapeutics Bolsters Global Patent PortfolioPremiumCompany Announcements
Defence Therapeutics’ Vaccine Shows Promise Against Pancreatic Cancer
PremiumCompany Announcements
Defence Therapeutics’ Vaccine Shows Pancreatic Cancer PromiseOptions Prices
Currently, No data available
---
Ownership Overview
1.66% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
98.34% Public Companies and
Individual Investors
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.46 and its highest was $2.74 in the past 12 months.
What is Defence Therapeutics’s market cap?
Currently, no data Available
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Nov 22, 2024 which is in 137 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 29, 2024. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.022.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 45,536,674 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
---
Defence Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-69.25%
Trailing 12-Months
Company Description
Defence Therapeutics
Defence Therapeutics Inc is engaged in the development of anti-body drug conjugates that improve the efficacy and safety of nano and protein-based pharmaceuticals used in the treatment of cancer.
---
Technical Analysis
---